Changes in glycoprotein IIb/IIIa inhibitor excess dosing with site-specific safety feedback in the CRUSADE initiative

BACKGROUND: Glycoprotein (GP) IIb/IIIa inhibitors can improve outcomes in patients with non–ST-segment elevation acute coronary syndromes (NSTE ACS) but raise the risk of bleeding, particularly if dosed in excess. The impact of GP IIb/IIIa dosing feedback on safety and major bleeding is unknown. MET...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Mudrick, Daniel W., Chen, Anita Y., Roe, Matthew T., Newby, L. Kristin, Gibler, W. Brian, Ohman, E. Magnus, Peterson, Eric D., Alexander, Karen P.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2010
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3058758/
https://ncbi.nlm.nih.gov/pubmed/21146660
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ahj.2010.08.008
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak